Immunovant (IMVT)
(Real Time Quote from BATS)
$27.37 USD
-0.38 (-1.37%)
Updated Apr 26, 2024 03:28 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Immunovant, Inc. (IMVT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$49.56 | $57.00 | $32.00 | 78.59% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Immunovant, Inc. comes to $49.56. The forecasts range from a low of $32.00 to a high of $57.00. The average price target represents an increase of 78.59% from the last closing price of $27.75.
Analyst Price Targets (16)
Broker Rating
Immunovant, Inc. currently has an average brokerage recommendation (ABR) of 1.06 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.06 a month ago based on 17 recommendations.
Of the 16 recommendations deriving the current ABR, 15 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 93.75% and 6.25% of all recommendations. A month ago, Strong Buy made up 94.12%, while Buy represented 5.88%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 15 | 15 | 16 | 15 | 13 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.06 | 1.06 | 1.06 | 1.06 | 1.07 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
1/12/2024 | Cantor Fitzgerald & Co | Louise Chen | Not Available | Strong Buy |
10/25/2023 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
10/25/2023 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
9/27/2023 | Raymond James | Danielle Brill | Moderate Buy | Moderate Buy |
9/27/2023 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
9/26/2023 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
9/26/2023 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.06 |
ABR (Last week) | 1.06 |
# of Recs in ABR | 16 |
Average Target Price | $49.56 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.43 |